Advice
Following a resubmission
dexrazoxane (Savene®) is not recommended for use within NHS Scotland for the treatment of anthracycline extravasation.
Data from non-comparative, open-label phase II/III studies indicate that administration of dexrazoxane is associated with a relatively low rate of surgery and adverse sequelae following extravasation of anthracyclines.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC and in addition the justification of the treatment’s cost in relation to its health benefits was not sufficient.
Download detailed advice63KB (PDF)
Medicine details
- Medicine name:
- dexrazoxane (Savene)
- SMC ID:
- 361/07
- Indication:
- Anthracycline extravasation
- Pharmaceutical company
- TopoTarget A/S
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 13 October 2008